Loading...
Docoh

GSK (GSK)

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team (CET). The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The CET segment refers to the management of business activities. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

GSK stock data

Calendar

8 Mar 22
20 May 22
Quarter (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
2 Jul 21 GSK Common Stock Buy Acquire P Yes No 18 275,000 4.95M 1,007,583
2 Jul 21 GSK Common Stock Conversion Acquire C Yes No 0 635,646 0 732,583
2 Jul 21 GSK Common Stock Conversion Acquire C Yes No 0 27,345 0 96,937
2 Jul 21 GSK Common Stock Conversion Acquire C Yes No 0 8,380 0 69,592
2 Jul 21 GSK Common Stock Conversion Acquire C Yes No 0 14,917 0 61,212
2 Jul 21 GSK Common Stock Conversion Acquire C Yes No 0 12,979 0 46,295
2 Jul 21 GSK Common Stock Conversion Acquire C Yes No 0 1,505 0 33,316
2 Jul 21 GSK Series G Preferred Stock Common Stock Conversion Dispose C Yes No 0 10,055,408 0 0
2 Jul 21 GSK Series F-2 Preferred Stock Common Stock Conversion Dispose C Yes No 0 1,081,434 0 0
2 Jul 21 GSK Series E-2 Preferred Stock Common Stock Conversion Dispose C Yes No 0 331,399 0 0
13.0% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 884 890 -0.7%
Opened positions 104 187 -44.4%
Closed positions 110 67 +64.2%
Increased positions 331 307 +7.8%
Reduced positions 258 238 +8.4%
13F shares Current Prev Q Change
Total value 14.37B 14.41B -0.3%
Total shares 330.32M 326.9M +1.0%
Total puts 3.95M 2.62M +51.0%
Total calls 4.88M 10.78M -54.7%
Total put/call ratio 0.8 0.2 +233.7%
Largest owners Shares Value Change
Dodge & Cox 85.75M $3.74B -3.1%
Capital International Investors 19.1M $832.01M -0.1%
Fisher Asset Management 18.97M $826.21M +4.1%
FMR 16.92M $736.84M -4.7%
TROW T. Rowe Price 15.19M $661.56M +0.4%
Renaissance Technologies 10.01M $436.12M -2.1%
Arrowstreet Capital, Limited Partnership 9.62M $419.11M +32.5%
Black Creek Investment Management 9.21M $401.13M -11.2%
JTC Employer Solutions Trusteee 9.02M $392.74M +50.4%
STT State Street 8.99M $397.4M -0.1%
Largest transactions Shares Bought/sold Change
JTC Employer Solutions Trusteee 9.02M +3.02M +50.4%
Dodge & Cox 85.75M -2.77M -3.1%
NMR Nomura 1.94M -2.45M -55.8%
Arrowstreet Capital, Limited Partnership 9.62M +2.36M +32.5%
GS Goldman Sachs 7.11M +2.32M +48.3%
Marshall Wace 2.23M +2.23M NEW
Two Sigma Investments 7.16K -1.92M -99.6%
Acadian Asset Management 3.4M +1.61M +90.1%
Camber Capital Management 1M -1.5M -60.0%
Healthcare Of Ontario Pension Plan Trust Fund 0 -1.3M EXIT

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: accessible, adjuvant, Africa, ambition, andXevudy, Anne, antibody, antisense, August, Beal, bepirovirsen, bictegravir, Biktarvy, box, cabotegravir, cabozantinib, Canadian, cancer, categorisation, cephalosporin, CH, characterised, circa, circulation, clarity, cohort, CombinedTivicay, component, COVID, depemokimab, Device, Diagnostic, Dietz, difficult, digitalisation, disappointing, disciplined, distancing, distrust, dosing, drag, drove, Endorsement, engineering, exceeding, exemplar, FluLaval, freight, fuelling, fulfilment, geopolitical, Gilead, GLT, guided, Haleon, halving, HBV, headroom, hemisphere, hesitancy, highlighted, ID, immunology, inBlenrep, includingNucala, includingSeretide, inDovato, Ineffective, inflationary, inFluarix, infringement, Ingredient, inhaled, injectable, internationally, invalidating, invasion, labour, lethality, licence, lowerShingrix, maximising, meaningfully, misinformation, monetise, monoclonal, mRNA, ofArnuity, ofXevudy, oligonucleotide, omnichannel, onset, ovarian, payout, percent, perception, pharma, PIPL, pivotal, plastic, predict, preparatory, preserve, primarilyShingrix, quantify, rare, raw, rebound, rebounded, regimensJuluca, Rejection, reliant, render, retaliatory, risky, RSV, run, Russia, Ryan, slightly, Smoker, southern, sovereignty, Spain, stable, staffing, suppressed, susceptible, synthetic, temporary, theTivicay, tolerance, toXyzal, track, treatmentsand, tubing, Ukraine, underperform, unprecedented, unrepeated, unsolicited, Vitro, whereTrelegy, White, wholly, withBenlysta, Xevudy
Removed: acceptable, accomplish, Advair, Brexit, build, candidate, capable, Cervarix, CET, collected, contaminated, content, core, cyclical, declined, deed, demerge, desired, detrimental, disaster, discounting, discourse, dramatic, emergency, evolve, execute, exit, experienced, favorable, flat, footprint, franchise, functional, impede, impeded, influenza, initiate, innate, interpreted, Judy, lawfully, leverage, Lewent, license, lose, manufacturer, marketplace, mitigation, notable, organisation, packaging, play, preferred, prevented, produce, progression, proprietary, reaching, realized, recapitalization, reimbursed, remediate, retrieval, Rotarix, selected, sharing, storage, suspension, Synflorix, Tabular, terrorism, traded, unreasonable, unrest, weaker